Xeris Biopharma Holdings (0A8E) Stock Overview
A commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
0A8E Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.40 |
| 52 Week High | US$8.50 |
| 52 Week Low | US$2.75 |
| Beta | 0.90 |
| 1 Month Change | 6.88% |
| 3 Month Change | 76.19% |
| 1 Year Change | 180.49% |
| 3 Year Change | 430.01% |
| 5 Year Change | n/a |
| Change since IPO | 311.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A8E | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 3.1% | 12.0% | 2.2% |
| 1Y | 180.5% | 5.4% | 13.4% |
Return vs Industry: 0A8E exceeded the UK Pharmaceuticals industry which returned 5.4% over the past year.
Return vs Market: 0A8E exceeded the UK Market which returned 13.4% over the past year.
Price Volatility
| 0A8E volatility | |
|---|---|
| 0A8E Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.4% |
Stable Share Price: 0A8E's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A8E's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 394 | John Shannon | www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
| 0A8E fundamental statistics | |
|---|---|
| Market cap | US$1.32b |
| Earnings (TTM) | -US$32.00m |
| Revenue (TTM) | US$246.03m |
Is 0A8E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A8E income statement (TTM) | |
|---|---|
| Revenue | US$246.03m |
| Cost of Revenue | US$43.70m |
| Gross Profit | US$202.33m |
| Other Expenses | US$234.33m |
| Earnings | -US$32.00m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 82.24% |
| Net Profit Margin | -13.01% |
| Debt/Equity Ratio | -1,132.5% |
How did 0A8E perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 12:33 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xeris Biopharma Holdings, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Brandon Folkes | H.C. Wainwright & Co. |